GLP-1 medicines for type 2 diabetes

What “glycemic control” means in the labels

Each diabetes label uses nearly the same words: the medicine is added to diet and exercise to improve glycemic control, which simply means blood sugar control. In the clinical studies sections, the main measure is HbA1c ^[1].

MedlinePlus explains that HbA1c reflects your average blood sugar over the past two to three months: it measures how much hemoglobin in red blood cells has glucose attached, and those cells live about three months. A home glucose reading shows one moment; HbA1c shows the trend ^[19].

Type 2 diabetes labels at a glance

How they lower blood sugar

The labels describe the same core actions. These medicines raise insulin release and lower glucagon release, but mainly when blood sugar is high; the Ozempic® label calls this glucose-dependent. The same label adds that a slight delay in stomach emptying soon after meals is part of how blood sugar comes down ^[1].

Because the insulin push weakens as blood sugar falls, the labels tie the main low-sugar risk to combinations: their hypoglycemia warnings centre on use with insulin or a sulfonylurea, and the diabetes labels tell prescribers that the dose of those other medicines may need to come down ^[1][3].

The outcome trials behind the heart and kidney claims

Each heart or kidney indication rests on one large trial reported in section 14 of that label. The trials differ in who they enrolled, how long they ran and what they compared against, so their results are not a ranking.

What a review of the trials adds

A systematic review and meta-analysis published in 2021 pooled eight placebo-controlled outcome trials of GLP-1 receptor agonists with 60,080 people with type 2 diabetes. Overall, major cardiovascular events were 14% lower (hazard ratio 0.86), deaths from any cause 12% lower, hospital admission for heart failure 11% lower and a combined kidney outcome 21% lower, with no rise in severe hypoglycemia, retinopathy or pancreatic side effects ^[13].

A pooled analysis averages trials of different molecules, doses and populations, and this one predates several later trials, including SURPASS-CVOT and FLOW. It describes groups, not what will happen to one person, and it does not replace the label of the medicine you take.

Heart and kidney wording, label by label

Five diabetes labels now include an indication to reduce the risk of major adverse cardiovascular events, meaning cardiovascular death, non-fatal heart attack or non-fatal stroke. The wording differs. Ozempic® and Victoza® cover adults with established cardiovascular disease, Trulicity® adds people with several risk factors, and Rybelsus®, Ozempic® tablets and Mounjaro® describe adults at high risk of these events ^{[1][2][3][4][5]}.

Ozempic® is the only one with a kidney indication. For adults who have both type 2 diabetes and chronic kidney disease, it covers lowering the risk of a lasting fall in kidney function, of end-stage kidney disease and of death from cardiovascular causes ^[1]. These are extra indications on top of blood sugar control, not separate products.

How Europe and Canada word the same uses

• European Union: the Ozempic® product information is indicated for adults with insufficiently controlled type 2 diabetes, on its own when metformin is unsuitable or added to other diabetes medicines. Effects on heart and kidney events are described as trial results in section 5.1, not as separate indications ^[14].
• Canada, Victoza®: the heart indication is to reduce the incidence of cardiovascular death in adults with type 2 diabetes and established heart disease, a single component rather than the three-part composite ^[16].
• Canada, Trulicity®: the heart indication is to reduce the risk of non-fatal stroke, and Health Canada has not authorised use in people under 18 ^[15].
• Canada, Mounjaro®: the June 2026 monograph covers adults and young people aged 10 to under 18 with type 2 diabetes but lists no heart-events indication ^[17].

Children with type 2 diabetes

Three current US labels are approved from age 10: Mounjaro®, Trulicity® and Victoza®. Mounjaro® added this group in December 2025, according to its list of recent changes ^[3][4][5]. Bydureon BCise® was also labelled from age 10 before its approval was withdrawn ^[7][8].

Byetta® was never an option for children: its last label noted that effectiveness was not shown in a study of 120 children aged 10 to 17 ^[6]. The Ozempic® and Rybelsus® labels are for adults ^[1][2]. Whether one is suitable for a child is for the child’s diabetes team to decide.

What about the weight-management labels?

Wegovy®, Zepbound®, Saxenda® and Foundayo™ are not approved to treat type 2 diabetes, but each weight program included people with it. Weight fell less in those trials than in people without diabetes: in Wegovy® Study 3 the change at 68 weeks was −9.6% against −3.4% on placebo, and in Zepbound® Study 2 it was −12.8% and −14.7% on 10 and 15 mg against −3.2% at 72 weeks ^[9][10]. Saxenda® Study 2 reported −5.4% against −1.7% at 56 weeks, and Foundayo™ Trial 2 −9.6% on the highest dose against −2.5% at 72 weeks ^[11][12].

The Wegovy® label states that its injection gave less weight reduction in people with type 2 diabetes than in those without, and that its tablets have not been studied for weight reduction in this group. It asks for blood sugar monitoring before and during treatment in people with diabetes, and Saxenda® asks the same of adults with type 2 diabetes. The Saxenda® label also notes that liraglutide at the 1.8 mg Victoza® dose is the one used for type 2 diabetes, and that doses below 3 mg have not been shown to work for weight ^[9][11].

Warnings that matter most in diabetes

• Low blood sugar with insulin or sulfonylureas: the labels ask that you learn the signs and how to respond; the Medication Guide lists dizziness, sweating, shakiness, confusion, fast heartbeat and hunger among them ^[1].
• Diabetic eye disease: in a two-year trial the Ozempic® label reports retinopathy complications in 3.0% on semaglutide against 1.8% on placebo, rising to 8.2% against 5.2% in people with a history of retinopathy. A rapid improvement in blood sugar has been linked to temporary worsening, and people with a history of retinopathy should be monitored ^[1]. The Mounjaro® label added a matching monitoring warning in August 2026 ^[3].
• Stomach side effects and dehydration, which can affect the kidneys, especially while doses are being raised ^[1].
• Every current diabetes label carries the boxed warning about thyroid C-cell tumours seen in rodents; the withdrawn Byetta® label was the exception ^[1][6].

Ozempic®, Rybelsus®, Victoza®, Wegovy® and Saxenda® are registered trademarks of Novo Nordisk A/S. Mounjaro®, Trulicity® and Zepbound® are registered trademarks of Eli Lilly and Company; Foundayo™ is a trademark of Eli Lilly and Company. Byetta® and Bydureon BCise® are trademarks of the AstraZeneca group of companies. PepLabo is not affiliated with or endorsed by Novo Nordisk, Eli Lilly and Company or AstraZeneca.